Tech Company Financing Transactions
Aura Biosciences Funding Round
On 9/30/2016, Aura Biosciences landed $8 million in financing from Advent International, Alexandria Venture Investments and Chiesi Ventures.
Transaction Overview
Company Name
Announced On
9/30/2016
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance to the clinic Aura's lead program in ocular melanoma (OM), AU-011, which is the first targeted therapy ever to be developed for the primary treatment of this rare and life-threatening disease. AU-011 has been granted orphan drug designation by the U.S. Food and Drug Administration and is expected to enter clinical testing early next year.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
85 Bolton St.
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
Aura Biosciences is developing a new class of therapies to target and selectively destroy tumor cells. Its lead program in ocular melanoma, developed under a CRADA with the National Cancer Institute (NCI), has been granted orphan drug status by the US Food and Drug Administration.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Elisabet de los Pinos
Chief Financial Officer
Julie Feder
Chief Medical Officer
Cadmus Rich
Browse more venture capital transactions:
Prev: 9/30/2016: Cyberhaven venture capital transaction
Next: 9/30/2016: Simpplr venture capital transaction
Share this article
Where The Data Comes From
We record all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs